Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Medtronic
Harvard Business School
Citi
Baxter
Healthtrust
Boehringer Ingelheim
UBS
Deloitte

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076962

« Back to Dashboard

NDA 076962 describes BROMOCRIPTINE MESYLATE, which is a drug marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Paddock Llc, and Sandoz Inc, and is included in six NDAs. It is available from ten suppliers. Additional details are available on the BROMOCRIPTINE MESYLATE profile page.

The generic ingredient in BROMOCRIPTINE MESYLATE is bromocriptine mesylate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Summary for 076962
Tradename:BROMOCRIPTINE MESYLATE
Applicant:Mylan
Ingredient:bromocriptine mesylate
Patents:0
Therapeutic Class:Antiparkinson Agents
Hormonal Agents, Suppressant (Pituitary)
Formulation / Manufacturing:see details
Pharmacology for NDA: 076962
Ingredient-typeErgolines
Medical Subject Heading (MeSH) Categories for 076962
Suppliers and Packaging for NDA: 076962
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 076962 ANDA KAISER FOUNDATION HOSPITALS 0179-0165 0179-0165-70 30 TABLET in 1 BOX, UNIT-DOSE (0179-0165-70)
BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 076962 ANDA Mylan Pharmaceuticals Inc. 0378-2042 0378-2042-93 30 TABLET in 1 BOTTLE, PLASTIC (0378-2042-93)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Sep 24, 2004TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
Chubb
Novartis
Daiichi Sankyo
Cipla
Queensland Health
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot